Skip to content

Inspection Record

Genzyme Corporation — FDA 483 Findings

US FDAInspected 2025-02-14Published 2026-10-27 3 findingsMaterial and supplier controlDeviation, CAPA, and investigationLabeling and packaging

Inspectors Lizaida Perez · Priscilla M PastranaThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

Examination of packaging and labeling materials for suitability and correctness before packaging operations is not performed.

2Deviation, CAPA, and investigation

Written records are not always made of investigations into unexplained discrepancies.

3Labeling and packaging

Procedures designed to assure that correct labeling are used for drug products are not followed.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Genzyme Corporation findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.